Ascendis Pharma A's Cash & cash equivalent grew by 4.77 % in the Q4 2025 sequentially, faster than Current Liabilities, this led to improvement in Ascendis Pharma A's Quick Ratio to 0.59, Quick Ratio remained below Ascendis Pharma A average.

Within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Ascendis Pharma A in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 2440.

Explain Quick Ratio?
How much Cash & cash equivalents ASND�s has?
What are ASND�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ASND/financial-strength

https://api.csimarket.com/api/v1/companies/ASND/fundamentals

https://api.csimarket.com/api/v1/companies/ASND/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ASND Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	25.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	24.74 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.59	Subscribe	Subscribe	Subscribe	Subscribe
ASND's Total Ranking	# 2440	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	2.5 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	4.77 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 416
Healthcare Sector	# 768
Overall Market	# 2440

Quick Ratio Statistics
High	Average	Low
12.49	4.46	0.58
(Dec 31 2019)		(Dec 31 2025)

Financial Statements
Ascendis Pharma A's Current Liabilities	$ 1,228 Millions	Visit ASND's Balance sheet
Ascendis Pharma A's Cash & cash equivalent	$ 725 Millions	Visit ASND's Balance sheet
Source of ASND's Sales		Visit ASND's Sales by Geography

Cumulative Ascendis Pharma A's Quick Ratio

ASND's Quick Ratio for the trailling 12 Months

ASND Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	19.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	10.37 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.58	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4004	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	5.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	5.41 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ASND Financial Strength Comparisons >> Go to Compare ASND Quick Ratio to its Competitors

News about Ascendis Pharma A Quick Ratio

Ascendis Pharma Secures $150 Million Royalty Funding Agreement with Royalty Pharma to Drive Innovation in Endocrine Rare Disease Therapies,

Ascendis Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapies for rare endocrine diseases, has announced a significant financial milestone. The company has entered into a $150 million royalty funding agreement with Royalty Pharma, a renowned investor in healthcare royalties. This funding will be used to support the continued development and commercialization of Ascendis Pharmans endocrine rare disease products, including the highly anticipated U.S. commercial launch of YORVIPATH, as well as for general corporate purposes.
The agreement with Royalty Pharma comes at a crucial time for Ascendis Pharma as the company seeks to expand its reach and bring groundbreaking therapies to patients suffering from rare endocrine diseases. The funds will provide the necessary capital to advance ongoing clinical trials, conduct research and development activities, and support the commercialization efforts of YORVIPATH and other promising therapies in Ascendis Pharmans pipeline.

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q4 2025 to $1,227.63 millions, cumulative Quick Ratio remained unchanged at 0.58 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 483 other companies have achieved higher Quick Ratio than Ascendis Pharma A. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4004.

Explain Quick Ratio?
How much Cash & cash equivalents ASND�s has?
What are ASND�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 484
Healthcare Sector	# 992
Within the Market	# 4004

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.49	5.06	0.58
(Dec 31 2019)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Zai Lab Limited	1.62	$ 688.358 Millions	$ 424.417 Millions
Alaunos Therapeutics Inc	1.60	$ 1.385 Millions	$ 0.867 Millions
Fortress Biotech Inc	1.60	$ 79.381 Millions	$ 49.744 Millions
Geovax Labs Inc	1.59	$ 3.086 Millions	$ 1.937 Millions
Elite Pharmaceuticals Inc	1.58	$ 21.095 Millions	$ 13.358 Millions
Werewolf Therapeutics Inc	1.58	$ 57.050 Millions	$ 36.148 Millions
Therapeuticsmd Inc	1.56	$ 7.483 Millions	$ 4.785 Millions
Rigel Pharmaceuticals Inc	1.56	$ 154.955 Millions	$ 99.237 Millions
Emergent Biosolutions Inc	1.55	$ 205.400 Millions	$ 132.200 Millions
Integrated Biopharma Inc	1.50	$ 5.314 Millions	$ 3.541 Millions
60 Degrees Pharmaceuticals Inc	1.49	$ 2.751 Millions	$ 1.843 Millions
Maia Biotechnology Inc	1.48	$ 8.658 Millions	$ 5.836 Millions
Apellis Pharmaceuticals Inc	1.47	$ 466.233 Millions	$ 316.509 Millions
Alzamend Neuro Inc	1.46	$ 2.713 Millions	$ 1.857 Millions
Sarepta Therapeutics Inc	1.43	$ 939.650 Millions	$ 656.648 Millions
Legend Biotech Corporation	1.42	$ 901.900 Millions	$ 636.400 Millions
Indaptus Therapeutics Inc	1.38	$ 8.508 Millions	$ 6.159 Millions
Macrogenics Inc	1.38	$ 57.217 Millions	$ 41.586 Millions
Arcutis Biotherapeutics Inc	1.37	$ 178.075 Millions	$ 129.838 Millions
Addex Therapeutics Ltd	1.37	$ 1.639 Millions	$ 1.199 Millions
Inovio Pharmaceuticals Inc	1.34	$ 58.512 Millions	$ 43.669 Millions
Inventiva S a	1.31	$ 113.784 Millions	$ 86.663 Millions
Theriva Biologics inc	1.30	$ 13.056 Millions	$ 10.014 Millions
Moleculin Biotech Inc	1.30	$ 8.878 Millions	$ 6.854 Millions
Uniqure N v	1.28	$ 80.240 Millions	$ 62.919 Millions
Apimeds Pharmaceuticals US, Inc.	1.26	$ 13.273 Millions	$ 10.545 Millions
Vireo Growth Inc.	1.25	$ 103.230 Millions	$ 82.545 Millions
Vanda Pharmaceuticals Inc	1.24	$ 84.851 Millions	$ 68.297 Millions
Amicus Therapeutics inc	1.23	$ 293.536 Millions	$ 237.828 Millions
Nkarta Inc	1.23	$ 39.634 Millions	$ 32.122 Millions

Date modified: 2026-10-15T05:23:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.